AntriaBio Inc. raises additional $2 million
LOUISVILLE — AntriaBio Inc. (OTCQB: ANTB) this week announced that the company has raised another $2 million through a private placement offering to institutions and accredited investors.
Company officials said in a filing with the Securities and Exchange Commission that the new funds will be used for general corporate purposes and to help fund clinical studies of AB101, a once-a-week basal insulin for the treatment of type 1 and type 2 diabetes.
AntriaBio, headquartered at 1450 Infinite Drive, set up shop in Louisville early last year in hopes of resurrecting AB101, which originally was being developed by shuttered Fort Collins-based company PR Pharmaceuticals Inc.
SPONSORED CONTENT
How Platte River is proactively managing its clean energy transition costs
Learn more about how Platte River Power Authority is proactively managing its clean energy transition costs across the region.
LOUISVILLE — AntriaBio Inc. (OTCQB: ANTB) this week announced that the company has raised another $2 million through a private placement offering to institutions and accredited investors.
Company officials said in a filing with the Securities and Exchange Commission that the new funds will be used for general corporate purposes and to help fund clinical studies of AB101, a once-a-week basal insulin for the treatment of type 1 and type 2 diabetes.
AntriaBio, headquartered at 1450 Infinite Drive, set up shop in Louisville early last year in hopes of resurrecting AB101, which originally was being…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!